Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI
Conditions
Interventions
BI 671800
Placebo
Locations
14
United States
1268.53.01013 Boehringer Ingelheim Investigational Site
Huntington Beach, California, United States
1268.53.01014 Boehringer Ingelheim Investigational Site
Mission Viejo, California, United States
1268.53.01002 Boehringer Ingelheim Investigational Site
Stockton, California, United States
1268.53.01009 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1268.53.01011 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1268.53.01001 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts, United States
Start Date
March 1, 2010
Primary Completion Date
February 1, 2011
Completion Date
February 18, 2011
Last Updated
May 11, 2022
NCT06979323
NCT06664619
NCT07431021
NCT07383896
NCT06003569
NCT07356310
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions